Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in ...
The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...
Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...
At the 2026 AngloNordic conference, industry leaders highlighted a major shift toward AI-driven, non-animal testing methods in drug development, with Merck KGaA aiming to replace most animal protocols ...
In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...
Merck KGaA plans to replace most animal testing in drug development with advanced preclinical models over the next decade, aligning with a global regulatory push toward human-centric methods. The move ...
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results